ホーム › 前立腺がん › テネシー › Nashville
Nashville、TNにおける前立腺がんの臨床試験
Nashvilleとその周辺地域（約30マイル以内）の拠点で、前立腺がんに関する43件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
被験者募集中第1/2相
- GSK Investigational Site, Nashville
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
被験者募集中第3相
- Urology Associates, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- SCRI Oncology Partners, Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
被験者募集中第2相
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
被験者募集中第1相
- Tennessee Oncology, Nashville
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
- Urology Associates, Nashville
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
被験者募集中第3相
- Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Medical Oncology & Hematology Clinic, Nashville
- Tennessee Oncology, PLLC - Nashville Saint Thomas West, Nashville
- 他7件
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
被験者募集中第1相
- Tennessee Oncology, Nashville
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
被験者募集中第3相
- Sarah Cannon Research Institute Oncology Partners, Nashville
- United States Oncology Regulatory Affairs Corporate Office, Nashville
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
被験者募集中第3相
- Research Site, Nashville
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
被験者募集中第2相
- Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
被験者募集中第3相
- SCRI Oncology Partners ( Site 0074), Nashville
- Henry-Joyce Cancer Clinic ( Site 0042), Nashville
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
被験者募集中第1相
- Sarah Cannon Research Institute Oncology Partners, Nashville
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
被験者募集中第3相
- Urology Associates of Nashville, Nashville
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Center, Nashville
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
被験者募集中第2相
- Tennessee Oncology Nashville, Nashville
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
被験者募集中第1相
- SCRI Oncology Partners, Nashville
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
被験者募集中第3相
- Research Site, Nashville
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
被験者募集中第2相
- Sarah Cannon Research Institute, Nashville
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
被験者募集中第1相
- United States Oncology Regulatory Affairs Corporate Office, Nashville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
被験者募集中第2相
- Henry-Joyce Cancer Clinic, Nashville
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
被験者募集中第1相
- Sarah Cannon Research, Nashville
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
被験者募集中第1/2相
- Tennessee Oncology PLLC, Nashville
PSMA PET Combined With MRI for the Detection of PCa
被験者募集中第3相健康なボランティア歓迎
- Urology Associates of Nashville, Nashville
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Investigative Site #102, Nashville
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
被験者募集中第3相
- Vanderbilt University/Ingram Cancer Center, Nashville
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
被験者募集中第1相
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
被験者募集中第1相
- Urology Associates PC, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
被験者募集中観察研究健康なボランティア歓迎
- Vanderbilt-Ingram Cancer Center, Nashville
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute (SCRI), Nashville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
被験者募集中第1/2相
- Research Site 136, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Nashville
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
被験者募集中第3相
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #6, Nashville
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
被験者募集中第1/2相
- SCRI Oncology Partners, Nashville
他の都市における前立腺がんの試験
- New York City, NY103件の研究
- Houston, TX76件の研究
- Los Angeles, CA61件の研究
- Boston, MA59件の研究
- St. Louis, MO46件の研究
- Chicago, IL45件の研究
- San Francisco, CA45件の研究
- Philadelphia, PA44件の研究
- Baltimore, MD43件の研究
- Seattle, WA42件の研究
- Washington, DC38件の研究
- Dallas, TX36件の研究
Nashvilleにおける他の研究
- 非小細胞肺癌97件の研究
- 乳がん81件の研究
- 転移性癌70件の研究
- 大腸癌69件の研究
- がん（全種類）65件の研究
- 卵巣がん49件の研究
- 肺がん40件の研究
- 頭頸部扁平上皮癌39件の研究
- 膵臓がん39件の研究
- 子宮内膜がん38件の研究
- 悪性黒色腫33件の研究
- 多発性骨髄腫32件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。